Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy ImmunoGen stock

Learn how to easily invest in ImmunoGen stock.

ImmunoGen is a biotechnology business based in the US. ImmunoGen shares (IMGN) are listed on the NASDAQ and all prices are listed in US Dollars. ImmunoGen employs 277 staff and has a trailing 12-month revenue of around $108.8 million.

How to buy ImmunoGen stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – IMGN. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Easy to use platform with $0 stock trading & no annual fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100

Promoted for options trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+

ImmunoGen stock price (NASDAQ: IMGN)

Use our graph to track the performance of IMGN stocks over time.

ImmunoGen shares at a glance

Information last updated 2023-03-17.
Latest market close$3.93
52-week range$3.10 - $6.63
50-day moving average $4.35
200-day moving average $4.93
Wall St. target price$12.33
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.86

Buy ImmunoGen stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 7 of 7
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency, Futures
Get $100 - $2,000
when you you open and fund an account with $5,000 to $100,000+
Highly commended for Best Derivatives Trading Platform award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, ETFs, Cryptocurrency, Alternatives, Treasury Bills
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Diversify your portfolio by trading stocks, ETFs, T-Bills, crypto, rare collectibles and more.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs, Treasury Bills
Get $50 - $700
when you open and fund an account with $10,000 - $250,000+
Stocks, Bonds, Options, Mutual funds, ETFs, Futures
Get up to $600 or more
when you open and fund a new account.
E*TRADE offers commission-free stocks, access to mutual funds and advanced trading tools. Other fees apply.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy ImmunoGen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ImmunoGen price performance over time

Historical closes compared with the close of $3.93 from 2023-03-20

1 week (2023-03-15) -4.15%
1 month (2023-02-22) -0.51%
3 months (2022-12-22) -16.03%
6 months (2022-09-22) -16.38%
1 year (2022-03-21) -8.60%
2 years (2021-03-22) -54.72%
3 years (2020-03-20) 61.07%
5 years (2018-03-21) 12.5

ImmunoGen financials

Revenue TTM $108.8 million
Gross profit TTM $-104,764,000
Return on assets TTM -31.57%
Return on equity TTM -92.61%
Profit margin -204.93%
Book value $0.69
Market capitalisation $922.3 million

TTM: trailing 12 months

ImmunoGen share dividends

We're not expecting ImmunoGen to pay a dividend over the next 12 months.

ImmunoGen share price volatility

Over the last 12 months, ImmunoGen's shares have ranged in value from as little as $3.1 up to $6.63. A popular way to gauge a stock's volatility is its "beta".

IMGN.US volatility(beta: 0.94)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmunoGen's is 0.9442. This would suggest that ImmunoGen's shares are less volatile than average (for this exchange).

ImmunoGen overview

ImmunoGen, Inc. , a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc. ; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc. ; CytomX Therapeutics, Inc.

Frequently asked questions

What percentage of ImmunoGen is owned by insiders or institutions?
Currently 0.403% of ImmunoGen shares are held by insiders and 93.104% by institutions.
How many people work for ImmunoGen?
Latest data suggests 277 work at ImmunoGen.
When does the fiscal year end for ImmunoGen?
ImmunoGen's fiscal year ends in December.
Where is ImmunoGen based?
ImmunoGen's address is: 830 Winter Street, Waltham, MA, United States, 02451-1477
What is ImmunoGen's ISIN number?
ImmunoGen's international securities identification number is: US45253H1014
What is ImmunoGen's CUSIP number?
ImmunoGen's Committee on Uniform Securities Identification Procedures number is: 45253H101

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site